MCID: HYP014
MIFTS: 50

Hyperuricemia

Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 52 42 14 69
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 42 D033461
NCIt 47 C3961
UMLS 69 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as uricacidemia, is related to hyperuricemia, pulmonary hypertension, renal failure, and alkalosis and glomerulocystic kidney disease with hyperuricemia and isosthenuria, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics and Uricosurics Pathway, Pharmacodynamics. The drugs Allopurinol and Rasburicase have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 72 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
id Related Disease Score Top Affiliating Genes
1 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 12.1
2 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.1
3 autosomal dominant medullary cystic kidney disease with hyperuricemia 12.0
4 autosomal dominant medullary cystic kidney disease without hyperuricemia 12.0
5 hereditary hyperuricemia 11.8
6 lesch-nyhan syndrome 11.7
7 nephropathy familial with hyperuricemia 11.7
8 deafness hyperuricemia neurologic ataxia 11.7
9 nephronophthisis 11.6
10 hyperuricemic nephropathy, familial juvenile 2 11.4
11 hprt-related gout 11.4
12 hyperuricemic nephropathy, familial juvenile 1 10.9
13 glycogen storage disease ia 10.9
14 autosomal dominant tubulointerstitial kidney disease, ren-related 10.9
15 glycogen storage disease ib 10.9
16 familial juvenile hyperuricaemic nephropathy 10.7
17 hyperuricemic nephropathy, familial juvenile, 4 10.7
18 fructose intolerance, hereditary 10.7
19 glycogen storage disease ic 10.7
20 phosphoribosylpyrophosphate synthetase superactivity 10.7
21 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 10.7
22 medullary cystic kidney disease 2 10.6 HPRT1 SLC22A12 UMOD
23 diarrhea 4, malabsorptive, congenital 10.6 HPRT1 XDH
24 gout 10.6
25 overnutrition 10.6 HPRT1 XDH
26 repetitive stress injuries 10.5 INS REN
27 hyperammonemia due to carbonic anhydrase va deficiency 10.5 HPRT1 XDH
28 retinitis pigmentosa 68 10.4 G6PC INS
29 spinocerebellar ataxia 5 10.4 HPRT1 SLC22A12 SLC2A9
30 thrombotic thrombocytopenic purpura 10.4 REN UMOD
31 neutropenia 10.3 SLC22A12 SLC2A9 UMOD
32 chronic fungal otitis externa 10.3 CRP INS
33 kidney disease 10.2
34 obesity 10.2
35 pulmonary edema 10.1 CRP SLC2A9
36 myotonic cataract 10.1 CRP INS
37 cystinosis 10.1 CRP REN UMOD
38 van maldergem syndrome 10.1 HPRT1 SLC22A12 SLC2A9 XDH
39 perinephritis 10.1 G6PC INS PFKM
40 neuronal ceroid-lipofuscinoses 10.1 CRP G6PC
41 endotheliitis 10.1
42 heart disease 9.9
43 diabetic encephalopathy 9.9 CRP INS REN
44 periampullary adenoma 9.9 CRP INS REN
45 arthritis 9.9
46 fatty liver disease 9.9
47 liver disease 9.9
48 acute insulin response 9.9 CRP INS
49 lymphoma 9.9
50 atherosclerosis 9.9

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, polydipsia, muscle weakness, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 REN SLC22A12 SLC2A9 UMOD XDH ABCG2
2 behavior/neurological MP:0005386 10.02 ADRB3 G6PC HPRT1 INS PFKM REN
3 growth/size/body region MP:0005378 10.02 ADRB3 XDH APOB G6PC HPRT1 INS
4 adipose tissue MP:0005375 9.88 XDH ABCG2 ADRB3 INS SLC2A9 UMOD
5 immune system MP:0005387 9.85 ABCG2 APOB CRP HPRT1 INS PFKM
6 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
7 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 315-30-0 2094
2
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134774-45-1
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
4
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1 144060-53-7 134018
5
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
6
Probenecid Approved Phase 4,Phase 2 57-66-9 4911
7
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
8
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
9
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
10
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
11
Selenium Approved, Vet_approved Phase 4 7782-49-2
12
Canagliflozin Approved Phase 4 842133-18-0
13
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
16
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
18
Uric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-93-2 1175
19
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
20 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
21 Antioxidants Phase 4,Phase 3,Phase 2,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
24 insulin Phase 4,Phase 3
25 Insulin, Globin Zinc Phase 4,Phase 3
26 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
27 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
28 glucocorticoids Phase 4,Phase 2,Phase 3
29 Hormone Antagonists Phase 4,Phase 2,Phase 3
30 Hormones Phase 4,Phase 2,Phase 3
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
32 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Angiotensinogen Phase 4
36 Antihypertensive Agents Phase 4,Phase 3,Phase 2
37
Olmesartan medoxomil Phase 4 144689-63-4 130881
38 Antimitotic Agents Phase 4,Phase 2
39 Diacetylrhein Phase 4
40 Analgesics Phase 4,Phase 2
41 Analgesics, Non-Narcotic Phase 4,Phase 2
42 Antacids Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
44 Anti-Ulcer Agents Phase 4
45 Cyclooxygenase Inhibitors Phase 4
46 Gastrointestinal Agents Phase 4
47 Peripheral Nervous System Agents Phase 4,Phase 2
48
Proton pump inhibitors Phase 4
49 Hypoglycemic Agents Phase 4
50 Micronutrients Phase 4

Interventional clinical trials:

(show top 50) (show all 129)

id Name Status NCT ID Phase Drugs
1 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
2 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
3 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
4 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
6 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
7 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
8 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4 Allopurinol;Placebo
9 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
10 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
11 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
12 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
13 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
14 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
15 The Intervention of Multi-vitamin With Minerals to Hyperuricemia Recruiting NCT03218709 Phase 4
16 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Recruiting NCT02797028 Phase 4 Allopurinol
17 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Recruiting NCT02956278 Phase 4 Allopurinol
18 Pharmacogenetics of SGLT2 Inhibitors Enrolling by invitation NCT02462421 Phase 4 Canagliflozin
19 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Not yet recruiting NCT03200210 Phase 4 Febuxostat;Placebo
20 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
21 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Unknown status NCT02533648 Phase 3 2 capsules of allopurinol 150 mg daily for 3 month;2 capsules of lactose daily for 3 month
22 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
23 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
24 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
25 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
26 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
27 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
28 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
29 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
30 Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
31 Prednisone for Heart Failure Patients With Hyperuricemia Recruiting NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
32 Long-term Prednisone Use for End-stage Heart Failure Recruiting NCT02282683 Phase 2, Phase 3 prednisone
33 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Recruiting NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
34 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Recruiting NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
35 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Active, not recruiting NCT03100318 Phase 3 FYU-981;Benzbromarone
36 Study of FYU-981 in Hyperuricemia With or Without Gout Active, not recruiting NCT03006445 Phase 3 FYU-981
37 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
38 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
39 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active
40 Hyperuricemia on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2 Allopurinol
41 Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Completed NCT00995618 Phase 2 Tranilast;Febuxostat;Combination - Tranilast and Febuxostat
42 Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia Completed NCT01052987 Phase 2 Tranilast;Allopurinol;Combination - Tranilast and Allopurinol;400 mg Allopurinol;High dose combination
43 Genetics of Hyperuricemia Therapy in Hmong Completed NCT02371421 Phase 2 Allopurinol
44 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT02344862 Phase 2 FYU-981 High dose, (Oral daily dosing for 8 weeks);FYU-981 Middle dose, (Oral daily dosing for 8 weeks);FYU-981 Low dose, (Oral daily dosing for 8 weeks);Placebo, (Oral daily dosing for 8 weeks)
45 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT02416167 Phase 2 FYU-981;Placebo
46 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia Completed NCT02078219 Phase 2 RDEA3170;Allopurinol;Placebo
47 A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients Completed NCT02317861 Phase 1, Phase 2 RDEA3170;Febuxostat;Benzbromarone
48 Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout Completed NCT01336686 Phase 2 Arhalofenate;Arhalofenate;Placebo comparator;Colchicine
49 Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients Completed NCT01416402 Phase 2 Arhalofenate;Febuxostat;Colchicine
50 A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00741442 Phase 2 RDEA806;Placebo

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

39
Kidney, Heart, Endothelial, Liver, Skeletal Muscle, Bone, Thyroid

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 705)
id Title Authors Year
1
Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial. ( 28087178 )
2017
2
Anti-Gouty Arthritis and Antihyperuricemia Effects of Sunflower (Helianthus annuus) Head Extract in Gouty and Hyperuricemia Animal Models. ( 28929115 )
2017
3
Chicken or the Egg? Hyperuricemia, Insulin Resistance, and Hypertension. ( 28808070 )
2017
4
Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. ( 28821853 )
2017
5
Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits. ( 28940111 )
2017
6
Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population. ( 28243797 )
2017
7
The management of hyperuricemia: back to the pathophysiology of uric acid. ( 28952386 )
2017
8
Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. ( 28027534 )
2017
9
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( 28072551 )
2017
10
(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. ( 27951420 )
2017
11
ABCG2 Polymorphism Is Associated with Hyperuricemia in a Study of a Community-Based Korean Cohort. ( 28776340 )
2017
12
Novel PRPS1 gain-of-function mutation in a patient with congenital hyperuricemia and facial anomalies. ( 28742244 )
2017
13
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. ( 28904879 )
2017
14
Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. ( 28410765 )
2017
15
"Metabolically Healthy" Obesity and Hyperuricemia Increase Risk for Hypertension and Diabetes: 5-year Japanese Cohort Study. ( 28922565 )
2017
16
Prevalence of hyperuricemia and its related risk factors among preschool children from China. ( 28842671 )
2017
17
Incidence and Simple Prediction Model of Hyperuricemia for Urban Han Chinese Adults: A Prospective Cohort Study. ( 28085072 )
2017
18
Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study. ( 28953666 )
2017
19
The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3. ( 28915657 )
2017
20
Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study. ( 28076299 )
2017
21
Temporal Relationship Between Hyperuricemia and Insulin Resistance and Its Impact on Future Risk of Hypertension. ( 28808071 )
2017
22
Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. ( 28801121 )
2017
23
Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass. ( 28869042 )
2017
24
Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. ( 28807403 )
2017
25
The role of hyperuricemia on vascular endothelium dysfunction. ( 28928970 )
2017
26
The association of hyperuricemia and metabolic syndrome in Thai postmenopausal women. ( 28937289 )
2017
27
Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). ( 28794514 )
2017
28
Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. ( 28917080 )
2017
29
Total saponins from dioscorea septemloba thunb reduce serum uric acid levels in rats with hyperuricemia through OATP1A1 up-regulation. ( 27072969 )
2016
30
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. ( 27423335 )
2016
31
SIRT1 prevents hyperuricemia via the PGC-1I+/PPARI^-ABCG2 pathway. ( 27022940 )
2016
32
Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease? ( 27914592 )
2016
33
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. ( 27605442 )
2016
34
Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study. ( 27428212 )
2016
35
The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphomaa8c. ( 27641217 )
2016
36
Hyperuricemia is associated with the increase of insulin release in non-obese subjects with normal glucose tolerance. ( 27045210 )
2016
37
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'. ( 27211369 )
2016
38
Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction. ( 27937806 )
2016
39
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. ( 27980008 )
2016
40
Hyperferritinemia increases the risk of hyperuricemia in HFE-hereditary hemochromatosis. ( 27659401 )
2016
41
Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy. ( 27555289 )
2016
42
Single 4.5a88mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome. ( 27084514 )
2016
43
Association between anthropometric indices and hyperuricemia in rural area of China: Methodological issues. ( 28029414 )
2016
44
Hyperuricemia is an independent competing risk factor for atrial fibrillation. ( 27871785 )
2016
45
Hyperuricemia Protects Against Low Bone Mineral Density, Osteoporosis and Fractures: A Systematic Review And Meta-Analysis. ( 27636234 )
2016
46
Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study. ( 27061989 )
2016
47
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. ( 27784849 )
2016
48
Atherogenic Index of Plasma Predicts Hyperuricemia in Rural Population: A Cross-Sectional Study from Northeast China. ( 27598187 )
2016
49
Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study. ( 27853065 )
2016
50
Prognostic Role of Hyperuricemia in Acute Heart Failure. ( 27209408 )
2016

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

Pathways related to Hyperuricemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.39 HPRT1 XDH
2 10.1 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.1 ABCG2 PFKM SLC17A3 SLC22A12 SLC2A9 UMOD
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.77 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.58 G6PC INS PFKM
3 glucose transport GO:0015758 9.52 INS SLC2A9
4 cholesterol efflux GO:0033344 9.51 ABCG2 APOB
5 organic anion transport GO:0015711 9.49 SLC17A3 SLC2A9
6 drug transmembrane transport GO:0006855 9.48 ABCG2 SLC17A3
7 phosphate ion transmembrane transport GO:0035435 9.46 SLC17A1 SLC17A3
8 glycogen catabolic process GO:0005980 9.43 G6PC PFKM
9 phosphate ion transport GO:0006817 9.32 SLC17A1 SLC17A3
10 urate transport GO:0015747 9.26 SLC17A3 SLC22A12
11 glucose-6-phosphate transport GO:0015760 9.16 G6PC SLC17A3
12 organic acid transmembrane transport GO:1903825 9.13 SLC17A3 SLC22A12 SLC2A9
13 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.77 ABCG2 ADRB3 HPRT1 PFKM XDH
2 low-density lipoprotein particle receptor binding GO:0050750 9.32 APOB CRP
3 cholesterol transporter activity GO:0017127 9.26 ABCG2 APOB
4 insulin-like growth factor receptor binding GO:0005159 9.16 INS REN
5 sodium:phosphate symporter activity GO:0005436 8.96 SLC17A1 SLC17A3
6 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....